Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.
(2015) In Oncotarget 6(32). p.33306-33318- Abstract
- The relevance of the intrinsic subtypes for clinical management of metastatic breast cancer is not comprehensively established. We aimed to evaluate the prevalence and prognostic significance of drifts in tumor molecular subtypes during breast cancer progression. A well-annotated cohort of 304 women with advanced breast cancer was studied. Tissue microarrays of primary tumors and synchronous lymph node metastases were constructed. Conventional biomarkers were centrally assessed and molecular subtypes were assigned following the 2013 St Gallen guidelines. Fine-needle aspirates of asynchronous metastases were transcriptionally profiled and subtyped using PAM50. Discordant expression of individual biomarkers and molecular subtypes was... (More)
- The relevance of the intrinsic subtypes for clinical management of metastatic breast cancer is not comprehensively established. We aimed to evaluate the prevalence and prognostic significance of drifts in tumor molecular subtypes during breast cancer progression. A well-annotated cohort of 304 women with advanced breast cancer was studied. Tissue microarrays of primary tumors and synchronous lymph node metastases were constructed. Conventional biomarkers were centrally assessed and molecular subtypes were assigned following the 2013 St Gallen guidelines. Fine-needle aspirates of asynchronous metastases were transcriptionally profiled and subtyped using PAM50. Discordant expression of individual biomarkers and molecular subtypes was observed during tumor progression. Primary luminal-like tumors were relatively unstable, frequently adopting a more aggressive subtype in the metastases. Notably, loss of ER expression and a luminal to non-luminal subtype conversion was associated with an inferior post-recurrence survival. In addition, ER and molecular subtype assessed at all tumor progression stages were independent prognostic factors for post-recurrence breast cancer mortality in multivariable analyses. Our results demonstrate that drifts in tumor molecular subtypes may occur during tumor progression, conferring adverse consequences on outcome following breast cancer relapse. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8039009
- author
- Kimbung, Siker
LU
; Kovács, Anikó
; Danielsson, Anna
; Bendahl, Pär-Ola
LU
; Lövgren, Kristina
LU
; Stolt, Marianne Frostvik
; Tobin, Nicholas P
; Lindström, Linda
; Bergh, Jonas
; Einbeigi, Zakaria
; Fernö, Mårten
LU
; Hatschek, Thomas
and Hedenfalk, Ingrid
LU
(Less) - organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Oncotarget
- volume
- 6
- issue
- 32
- pages
- 33306 - 33318
- publisher
- Impact Journals
- external identifiers
-
- pmid:26375671
- wos:000363186600091
- scopus:84946025828
- pmid:26375671
- ISSN
- 1949-2553
- DOI
- 10.18632/oncotarget.5089
- language
- English
- LU publication?
- yes
- id
- 76ea4f20-b596-4aca-8d3b-15f4a6c4e907 (old id 8039009)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26375671?dopt=Abstract
- date added to LUP
- 2016-04-01 12:52:46
- date last changed
- 2022-01-27 08:07:03
@article{76ea4f20-b596-4aca-8d3b-15f4a6c4e907,
abstract = {{The relevance of the intrinsic subtypes for clinical management of metastatic breast cancer is not comprehensively established. We aimed to evaluate the prevalence and prognostic significance of drifts in tumor molecular subtypes during breast cancer progression. A well-annotated cohort of 304 women with advanced breast cancer was studied. Tissue microarrays of primary tumors and synchronous lymph node metastases were constructed. Conventional biomarkers were centrally assessed and molecular subtypes were assigned following the 2013 St Gallen guidelines. Fine-needle aspirates of asynchronous metastases were transcriptionally profiled and subtyped using PAM50. Discordant expression of individual biomarkers and molecular subtypes was observed during tumor progression. Primary luminal-like tumors were relatively unstable, frequently adopting a more aggressive subtype in the metastases. Notably, loss of ER expression and a luminal to non-luminal subtype conversion was associated with an inferior post-recurrence survival. In addition, ER and molecular subtype assessed at all tumor progression stages were independent prognostic factors for post-recurrence breast cancer mortality in multivariable analyses. Our results demonstrate that drifts in tumor molecular subtypes may occur during tumor progression, conferring adverse consequences on outcome following breast cancer relapse.}},
author = {{Kimbung, Siker and Kovács, Anikó and Danielsson, Anna and Bendahl, Pär-Ola and Lövgren, Kristina and Stolt, Marianne Frostvik and Tobin, Nicholas P and Lindström, Linda and Bergh, Jonas and Einbeigi, Zakaria and Fernö, Mårten and Hatschek, Thomas and Hedenfalk, Ingrid}},
issn = {{1949-2553}},
language = {{eng}},
number = {{32}},
pages = {{33306--33318}},
publisher = {{Impact Journals}},
series = {{Oncotarget}},
title = {{Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.}},
url = {{http://dx.doi.org/10.18632/oncotarget.5089}},
doi = {{10.18632/oncotarget.5089}},
volume = {{6}},
year = {{2015}},
}